Methylphenidate-associated chest pain in a child

Area of Science:

• Pediatric Neurology
• Child Psychiatry
• Clinical Pharmacology

Background:

• Autism spectrum disorder (ASD) and attention-deficit/hyperactivity disorder (ADHD) frequently co-occur in children.
• Stimulant medications like methylphenidate are common treatments for ADHD symptoms, including hyperactivity and impulsivity.
• Assessing and managing potential side effects is crucial in pediatric psychopharmacology.

Observation:

• A young child diagnosed with ASD and comorbid ADHD exhibited significant hyperactivity, impulsivity, and poor safety awareness.
• Methylphenidate was initiated to manage ADHD symptoms, improving behavior but leading to the development of chest pain after eight months.
• The stimulant medication was discontinued due to the adverse cardiac event.

Findings:

• The cessation of methylphenidate resulted in the complete resolution of the child's chest pain.
• Subsequent treatment with atomoxetine, a non-stimulant medication, was well-tolerated without recurrence of cardiac symptoms.
• This case illustrates a potential cardiac side effect associated with methylphenidate use in a pediatric population.

Implications:

• Clinicians should be vigilant for cardiac side effects when prescribing methylphenidate to children, particularly those with comorbid conditions.
• Atomoxetine may represent a viable alternative for ADHD treatment in pediatric patients experiencing stimulant-induced cardiovascular adverse events.
• Further research into the cardiovascular safety profile of stimulant and non-stimulant ADHD medications in children with ASD is warranted.